InvestorsHub Logo
Followers 34
Posts 14201
Boards Moderated 1
Alias Born 03/27/2014

Re: goodibag post# 20343

Friday, 12/08/2017 11:13:21 PM

Friday, December 08, 2017 11:13:21 PM

Post# of 37495
Try 2020 for the prescription based product. And, that's only if they're successful at a "fast track". Since there is no history of them succeeding at bringing any prescription drug from incubation to Market; odds are more likely than not that it'll be significantly longer than 3 years - since average time is 12 years

Q3 2018 for the non prescription product - which is NOV 2018-Jan 2019?


Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health's intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.

"By employing an FDA regulations-savvy, 'fast-track' pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development," said Omni Health's CEO, Andrey Soloviev. "Our projections set this target date at roughly three years out. It will be a strong competitor in a lucrative medicinal niche populated by a limited number of pain management products at exponentially higher valuations. Peer analysis shows these valuations to be in the range of $100 Million to $140 Million."

Additionally, Omni Health is in the final stages of development of non-prescription CBD analgesic creams and ointments with fast absorption properties which we are able to rapidly deploy to the market.

Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles.